Literature DB >> 31145129

The gut microbiota in type 1 diabetes: friend or foe?

Patrick G Gavin1, Emma E Hamilton-Williams.   

Abstract

PURPOSE OF REVIEW: Evidence is mounting that disturbances in the gut microbiota play a role in the rising incidence of type 1 diabetes (T1D) and new technologies are expanding our ability to understand microbial function and host interactions. Longitudinal data from large cohorts of children at risk of T1D are nor solidifying our understanding of the function of the microbiota in this disease. RECENT
FINDINGS: Although taxonomic changes in the gut microbiota associated with T1D are relatively modest, a functional defect in production of short-chain fatty acids (SCFAs) remains as a unifying feature across multiple studies and populations. Dysbiosis of the microbiota in T1D has been linked to decreased gut barrier and exocrine pancreas function. We explore factors contributing to the disturbed microbiota in T1D such as infant diet, probiotic use and genetic risk linked to defective immune regulation. We also discuss the interplay between immunotherapy, the gut immune response and the microbiota.
SUMMARY: Functional alterations in the microbiota are linked to pathogenesis of T1D and these findings provide a rationale for future investigations aimed at establishing a healthy microbiota and promoting SCFA production and prevention of T1D.

Entities:  

Year:  2019        PMID: 31145129     DOI: 10.1097/MED.0000000000000483

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  6 in total

1.  Exacerbation of Chikungunya Virus Rheumatic Immunopathology by a High Fiber Diet and Butyrate.

Authors:  Natalie A Prow; Thiago D C Hirata; Bing Tang; Thibaut Larcher; Pamela Mukhopadhyay; Tiago Lubiana Alves; Thuy T Le; Joy Gardner; Yee Suan Poo; Eri Nakayama; Viviana P Lutzky; Helder I Nakaya; Andreas Suhrbier
Journal:  Front Immunol       Date:  2019-11-26       Impact factor: 7.561

Review 2.  Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies.

Authors:  Gratiela Gradisteanu Pircalabioru; Nicolae Corcionivoschi; Ozan Gundogdu; Mariana-Carmen Chifiriuc; Luminita Gabriela Marutescu; Bogdan Ispas; Octavian Savu
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

3.  Modulation of Intestinal ILC3 for the Treatment of Type 1 Diabetes.

Authors:  Ivana Stojanović; Tamara Saksida; Đorđe Miljković; Nada Pejnović
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

Review 4.  Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

Review 5.  Taming the Sentinels: Microbiome-Derived Metabolites and Polarization of T Cells.

Authors:  Lukasz Wojciech; Kevin S W Tan; Nicholas R J Gascoigne
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

6.  Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events.

Authors:  Bei Tan; Min-Jiang Chen; Qi Guo; Hao Tang; Yue Li; Xin-Miao Jia; Yan Xu; Liang Zhu; Meng-Zhao Wang; Jia-Ming Qian
Journal:  Thorac Cancer       Date:  2021-05-04       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.